Yi et al. also found that stage II CRC patients with tumour-methylated IGFBP3 had worse survival than those with unmethylated IGFBP3 (P < 0.05), and the former might benefit from adjuvant chemotherapy [26]. The gene discussed is IGFBP3; the disease is neoplasm.